BioRestorative Therapies, Inc. Engages Consulting Firm to Advance brtxDISC™ Program Delivery Device Through FDA Clearance Process

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

JUPITER, Fla.--(BUSINESS WIRE)--BioRestorative Therapies, Inc. ("BRT" or the "Company") (OTCBB:BRTX), a life sciences company focused on developing stem cell-based therapies for personal medical applications, announced the engagement of the regulatory consultancy firm Phil Triolo and Associates, LC (“PTA”) to help advance the Company’s brtxDISC™ therapeutic procedure through the U.S. Food and Drug Administration (“FDA”) regulatory process. The brtxDISC™ program is the Company’s non-surgical investigative treatment for bulging and herniated lumbar discs.

Help employers find you! Check out all the jobs and post your resume.

Back to news